Küleon Bioscience

Küleon Bioscience is a pioneering pharmaceutical manufacturing company dedicated to discovering and developing the next generation of neuropsychiatric medicines. Located in SEATTLE, Washington 98107, US, Küleon Bioscience leverages proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders.

Küleon Bioscience has created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain, responsible for difficult-to-treat disorders such as schizophrenia and depression. The company has successfully identified several preclinical leads with significantly improved agonism characteristics, such as low-to-no hallucinogenic or cardiotoxic liability, and modified PK/PD profiles compared to other known atypical antipsychotics and serotonergic drugs. Küleon Bioscience's novel compounds are designed for functional selectivity via biased signaling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects.

With novel and patentable molecular scaffolds and compounds, Küleon Bioscience is strategically positioned in the market, as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. Küleon Bioscience is collaborating with leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space, ensuring continued innovation and growth. Küleon Bioscience is poised to make a significant impact on the future of neuropsychiatric medicine. We invite the management team to create a customized and exclusive company showcase and product listing on our platform.